Navigation Links
Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
Date:10/29/2007

VIENNA, Va., Oct. 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced today that it has published a very comprehensive review of cancer immunotherapies on its new website. The link is located in the top right hand corner of its home page at http://www.cel-sci.com .

Geert Kersten, Chief Executive Officer of CEL-SCI said, "Immunotherapy in the minds of many represents the future of cancer therapy. We have created an easy to navigate, interactive web based review that is designed to be helpful to doctors, patients as well as investors."

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R). In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. A Comprehensive CD-ROM On HIV/AIDS Released By Center for HIV Information
2. ‘Comprehensive Sex Education’ Favored Against ‘Abstinence-Only’ Progams
3. Comprehensive Reforms to Move Toward Patient-Centered Care
4. Australia Proposes Comprehensive Plans to Protect Aboriginal Children from Sexual Abuse
5. UK Sports Clubs Failing to Run Comprehensive Health Checks on Professional Players
6. FDA may speed review of new drugs
7. Scientists review SARS
8. US Reviews Risks Of Tamiflu After 12 Children Die
9. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
10. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
11. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... On Dec. 2, 2016, CURE® magazine will host the 4th ... 2016 MPN Heroes—eight individuals who have made a difference in the field of rare ... of care, demonstrating leadership within the MPN community and/or a commitment to individual patients. ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change ... Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch ... plan (Part D) need to make changes during this period order for their new ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... held the largest share in the ECG Cables And ... demand for remote monitoring ECG devices. On the other hand, ... to witness the highest growth rate during the forecast period. ... Dickinson and Company (U.S.), Medtronic plc ( Ireland ... and Mindray Medical International Limited ( China ), ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... Share, Development, Growth and Demand Forecast to 2022" report to their ... , , ... $6 billion in 2015, and it is expected to grow at a ... is expected to witness faster growth during the forecast period, a CAGR ...
(Date:12/2/2016)... SAN FRANCISCO , Dec. 2, 2016  PipelineRx, ... clinical telepharmacy, will be offering demonstrations of its ... American Society of Health-System Pharmacists 2016 Midyear Clinical ... Las Vegas . With nearly 300 hospital ... telepharmacy services and technology designed to dramatically improve ...
Breaking Medicine Technology: